Displaying drugs 176 - 200 of 219 in total
PRX-ASL
PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.
Investigational
Solnatide
Solnatide has been used in trials studying the treatment of Acute Lung Injury.
Investigational
Berubicin
Investigational
1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE
Experimental
MALP-2
Investigational
Autologous Human Peripheral Blood Lymphocytes
Investigational
VaxSyn
VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).
Investigational
L-Leucyl-L-prolyl-L-prolyl-L-seryl-L-arginine
Investigational
Posoleucel
Investigational
Nerofe
Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).
Investigational
Somatorelin
Somatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.
Investigational
Tonabacase
Investigational
LSTA1
Investigational
RP-A501
RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane protein 2 (LAMP-2). It is being investigated for Danon disease.
Investigational
CD8+ enriched young tumor infiltrating lymphocytes
Investigational
Camsirubicin
GPX-150 has been used in trials studying the treatment of Soft Tissue Sarcoma and Advanced Solid Tumors - Phase 1 Population.
Investigational
GO-203-2C
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Peptide YY (1-36)
Investigational
Clervonafusp alfa
Investigational
Edotreotide
Investigational
Zalifrelimab
Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
Investigational
Zamerovimab
Investigational
Reveglucosidase alfa
Investigational
Denecimig
Delpacibart is a humanized, bispecific, bivalent monoclonal antibody against coagulation factor 9.
Investigational
Displaying drugs 176 - 200 of 219 in total